Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Legal / IP

Peking Union Medical College Innovates with Angle Positioning Device Patent Sale

Fineline Cube Aug 27, 2024

Peking Union Medical College Hospital (PUMCH) has announced its intention to transfer the patent for...

Company Deals

China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO

Fineline Cube Aug 27, 2024

China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD...

Company

UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala

Fineline Cube Aug 27, 2024

UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced...

Company Deals

Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy

Fineline Cube Aug 27, 2024

Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...

Company Drug

Shanghai Fudan-Zhangjiang Enrolls First Patient in Phase III Trial for TROP2 ADC FDA018 in TNBC

Fineline Cube Aug 27, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, a China-based pharmaceutical company listed on the Hong Kong Stock...

Company Drug

China’s Guilin Sanjin Pharmaceutical Advances BC011 with NMPA Approval for Phase I Clinical Trial

Fineline Cube Aug 27, 2024

Guilin Sanjin Pharmaceutical Co. Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...

Company Deals

Guangzhou Boji Medical and CapitalBio Pharma Form Joint Venture to Innovate in Traditional Chinese Medicine

Fineline Cube Aug 27, 2024

Guangzhou Boji Medical Biotechnological Co., Ltd, a Clinical Research Organization (CRO) based in China and...

Company

Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report

Fineline Cube Aug 27, 2024

Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong...

Company Drug

Changchun High & New Technology Industries Receives FDA Approval for GenSci098 Clinical Trial in Thyroid Eye Disease

Fineline Cube Aug 27, 2024

Changchun High & New Technology Industries (Group) Inc., a Chinese corporation listed on the Shenzhen...

Company Drug

Diversifying HPV Protection: Beijing Wantai’s Vaccine Filing Competes with Gardasil 9 in China

Fineline Cube Aug 27, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai...

Company Drug

BeiGene Advances R/R CLL/SLL Treatment with FDA Fast-Tracked BGB-16673 in Phase I/II Clinical Trial

Fineline Cube Aug 27, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has been granted Fast...

Company

MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1

Fineline Cube Aug 27, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...

Company

Shanghai Pharmaceuticals Posts 5.14% YOY Revenue Growth in 2024H1 with Focus on Cell Therapies

Fineline Cube Aug 27, 2024

Shanghai Pharmaceuticals Holding Co. (SPH; HKG: 2607; SHA: 601607) has announced its financial results for...

Company

Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins

Fineline Cube Aug 27, 2024

Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control

Fineline Cube Aug 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Company Drug

China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors

Fineline Cube Aug 26, 2024

The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude...

Company Medical Device

Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions

Fineline Cube Aug 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...

Company Drug

Mabwell Bioscience Initiates Phase III Trial for 9MW2821 Combo in Urothelial Carcinoma Following NMPA Clearance

Fineline Cube Aug 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd, a biopharmaceutical company listed in China (SHA: 688062), has announced...

Company

CStone Pharmaceuticals Reports 2024 Interim Results with Strategic Collaborations and Regulatory Milestones

Fineline Cube Aug 26, 2024

CStone Pharmaceuticals, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Deals Medical Device

Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round

Fineline Cube Aug 26, 2024

Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for...

Posts pagination

1 … 299 300 301 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.